First Trust Value Line Dividend Index Fund

Most Recent

  • uploads///ANR
    Company & Industry Overviews

    Analysts’ Expectations for Sanofi

    According to a March 3, 2016, Bloomberg consensus of five brokerage firms, 60% of brokerage firms rated Sanofi as a “buy,” while 40% of the broker firms rated the company as a “hold.”

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    Teva Is Expected to See a Fall in Its Profit Margins in 2017

    Teva Pharmaceutical (TEVA) expects its 2017 non-generally accepted accounting principles (non-GAAP) earnings per share (or EPS) to fall in the range of $4.9–$5.3.

    By Margaret Patrick
  • uploads///AVB RENT EPS
    Real Estate

    AvalonBay: What’s Driving the Dividend and Valuations?

    AvalonBay’s revenue grew 7% in the first quarter, driven by rental and other income.

    By Amanda Lawrence
  • uploads///Graph
    Company & Industry Overviews

    The Latest on Fasinumab, a Teva-Regeneron Collaborative Drug

    On October 17, 2016, Teva and Regeneron announced that the FDA had placed the Phase 2 study for fasinumab on clinical hold.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    Sanofi’s Consumer Healthcare and Generics Franchises

    Sanofi’s (SNY) Consumer Healthcare franchise’s products include Allegra, Doliprane, and Nasacort. The segment reported a 3.1% decline in revenues at 905 million euros in 1Q16, compared to its 1Q15 revenues.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Sanofi: Analysts’ Recommendations on October 30

    As of October 30, four analysts are tracking Sanofi. Two analysts recommend a “strong buy,” while two analysts recommend a “hold.”

    By Mike Benson
  • uploads///drug _
    Earnings Report

    GlaxoSmithKline’s Q3 2018 Earnings: Analysts’ Estimates

    Analysts are expecting GlaxoSmithKline’s revenues to increase 2.3% to 8.02 billion pounds for the third quarter of 2018.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Novartis in Q3 2018: Analysts Expect Revenue Growth

    Analysts expect Novartis’s revenues to increase ~4.9% to $13.02 billion in the third quarter of 2018.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    A Look at the Performance of Novartis’s Alcon

    Alcon reported revenue of ~$1.82 billion in the second quarter, a 7% rise.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Novartis’s Sandoz Business Has Been Performing Recently

    Sandoz, Novartis’s (NVS) generics business, is a market leader in differentiated generics.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How GlaxoSmithKline’s Pharmaceutical Business Performed

    GlaxoSmithKline’s (GSK) Pharmaceutical segment includes various products from different therapeutic areas including respiratory products, HIV products, immuno-inflammation products, and established products.

    By Mike Benson
  • uploads///eye _
    Company & Industry Overviews

    Alcon Voluntarily Withdraws CyPass Micro-Stent from Global Market

    On August 29, Alcon announced that it had voluntarily withdrawn the CyPass Micro-Stent on a global basis, effective immediately.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    GlaxoSmithKline’s Pharmaceuticals Segment in Q2 2018

    GlaxoSmithKline’s (GSK) Pharmaceuticals segment includes its HIV, respiratory, immuno-inflammation, and established products.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Why GlaxoSmithKline’s Q2 2018 Revenues Are Expected to Decline

    The Pharmaceuticals segment is expected to report growth in operating revenues in Q2 2018 with a strong performance of new respiratory products.

    By Mike Benson
  • uploads///healthcre
    Healthcare

    How the Healthcare Sector’s Dividend Yield Stacks Up

    The healthcare industry has an average dividend yield of 1.9%.

    By Amanda Lawrence
  • uploads///Chart
    Company & Industry Overviews

    How Novartis’s Revenues Trended in 4Q17

    Novartis surpassed Wall Street analysts’ estimates for earnings per share (or EPS) with reported EPS of $4.86 as compared to estimates of $4.82 for 2017.

    By Mike Benson
  • uploads///ablynx sanofi partnership
    Company & Industry Overviews

    A Look at Ablynx and Sanofi’s Existing Partnership

    On January 29, 2018, Sanofi (SNY) announced that it had agreed to acquire Ablynx (ABLX) for 3.9 billion euros.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    Trelegy Ellipta May Emerge as Major Growth Driver for GlaxoSmithKline

    Trelegy Ellipta could enable GlaxoSmithKline to compete aggressively with other respiratory players such as Novartis (NVS).

    By Margaret Patrick
  • uploads///Tafinlar
    Company & Industry Overviews

    How Is Novartis’s Tafinlar+Mekinist Positioned for 2018?

    In 1Q17, 2Q17, and 3Q17, Tafinlar+Mekinist reported revenues of $187 million, $216 million, and $224 million, respectively.

    By Daniel Collins
  • uploads///div pri gro aiz
    Financials

    Why Assurant Has a Positive Outlook despite a Weak 2017

    Assurant’s (AIZ) revenue fell 27% and 18% in 2016 and 9M17, respectively.

    By Amanda Lawrence
  • uploads///Respiratory
    Company & Industry Overviews

    Behind Novartis’s Respiratory Drug Performance in 3Q17

    In 3Q17, Novartis’s COPD (Chronic Obstructive Pulmonary Disorder) portfolio reported revenues of $165 million, which with ~2% higher YoY and 1% higher QoQ.

    By Daniel Collins
  • uploads///REV EPS AIZ
    Financials

    A Look at Assurant, Another Top Dividend Grower

    Assurant’s revenue and earnings in 2015 and 2016 Assurant’s (AIZ) revenue fell 1% and 27% in 2015 and 2016, respectively. Its US revenue rose in 2015 before falling in 2016, and its international revenue fell in both years, along with its net earned premiums, net investment income, and net realized gains on investments. Its fees and other […]

    By Amanda Lawrence
  • uploads///Graph
    Company & Industry Overviews

    Sanofi’s Kevzara Could Be Solid Addition to Rheumatoid Arthritis

    Launched in US markets in June 2017, Kevzara (sarilumab), Sanofi (SNY) and Regeneron’s (REGN) IL-6 receptor antibody, has received favorable feedback from the physician community.

    By Margaret Patrick
  • uploads///SRE
    Energy & Utilities

    What Led to Sempra Energy’s Sharp Fall in Dividend Yield?

    Sempra Energy’s revenue for the first half of 2017 rose 7.0%, driven by every segment.

    By Amanda Lawrence
  • uploads///Promacta Votrient jakavi
    Company & Industry Overviews

    How Novartis’s Promacta, Votrient, and Jakavi Performed in 1H17

    In 1H17, Novartis’s (NVS) Promacta/Revolade reported revenues of around $385 million, which reflected ~33% growth on a year-over-year (or YoY) basis.

    By Daniel Collins
  • uploads///Analysts Ratings
    Company & Industry Overviews

    What Analysts Recommend for Novartis in September 2017

    Three analysts were analyzing Novartis in September 2017. One analyst recommended a “strong buy,” while the other two recommended a “hold.”

    By Daniel Collins
  • uploads///FTI PRICE
    Miscellaneous

    What Could Drive TechnipFMC’s Dividend Yield

    How TechnipFMC intends to maintain its yield FMC Technologies and Technip merged to become TechnipFMC (FTI) in 2017, an international provider of subsea, onshore, offshore, and surface projects. The synergy aims to combat the challenges of low oil prices and a challenging outlook through cost cutting and the enhancement of efficiency. The company recorded 51% revenue […]

    By Amanda Lawrence
  • uploads///Chart  Rev
    Company & Industry Overviews

    GlaxoSmithKline Reported Revenue Growth in 2Q17

    GlaxoSmithKline (GSK) reported revenues of 7.32 billion pounds in 2Q17—12% growth compared to revenues of 6.53 billion pounds in 2Q16.

    By Mike Benson
  • uploads///Chart  Segment
    Company & Industry Overviews

    Inside Novartis’s 2Q17 Revenues

    Novartis (NVS) reported flat revenues of $12.24 billion on a constant-currency basis for 2Q17. This included a 2% decline due to foreign exchange.

    By Mike Benson
  • uploads///Chart  Rev EPS
    Company & Industry Overviews

    Bristol-Myers Squibb’s Valuation after 2Q17 Earnings

    Bristol-Myers Squibb (BMY) met Wall Street analysts’ estimate for EPS at $0.74. It also surpassed the estimates for revenues.

    By Mike Benson
  • uploads///DY BEN
    Financials

    Dividend Yield of Franklin Resources

    Franklin Resources (BEN) has recorded consistent growth in dividends since at least March 1982.

    By Amanda Lawrence
  • uploads///Chart  GCHC
    Company & Industry Overviews

    Sanofi’s General Medicines and Consumer Healthcare in 2Q17

    General Medicines Sanofi’s (SNY) generic business contributed ~5.1% of its total revenue in 2Q17. The business reported revenue of 442 million euros in 2Q17, an 8% decrease from 2Q16. Revenue fell due to lower sales in US markets, European markets, and emerging markets. This fall was partially offset by the growth in the rest of […]

    By Mike Benson
  • uploads///Chart  Val
    Company & Industry Overviews

    A Look at Sanofi’s Post-2Q17 Valuation

    Sanofi (SNY), one of the world’s largest pharmaceutical companies, reported operational growth of 5.5% to reach revenue of 8.7 billion euros in 2Q17.

    By Mike Benson
  • uploads///TGTVS
    Consumer

    Target’ s Performance as a Dividend Aristocrat

    Target’s (TGT) sales for 2016 fell 6.0% due to lower comparable store sales and weak store traffic.

    By Amanda Lawrence
  • uploads///INTC
    Consumer

    Have Intel and Procter & Gamble Been Able to Increase Dividends?

    Intel (INTC) released its 2Q17 results on July 27, 2017. The company’s revenue and EPS for the first half of 2017 rose 8.5% and 72.0%, respectively.

    By Amanda Lawrence
  • uploads///Chart  Pharma
    Earnings Report

    GSK’s 2Q17 Earnings: Pharmaceuticals Segment

    GSK’s Pharmaceuticals segment’s contribution to the company’s total revenues was 59.5% in 2Q17.

    By Mike Benson
  • uploads///ABR
    Financials

    Arbor Realty Trust’s Dividend Growth Prospects

    Arbor Realty Trust (ABR) paid 74.1% of its earnings as dividends in 2016 compared to 56.7% in 1Q17.

    By Amanda Lawrence
  • uploads///Chart  Revenue
    Earnings Report

    Unpacking GlaxoSmithKline’s 2Q17 Revenue Expectations

    Analysts expect to see a growth of ~11.4% in GlaxoSmithKline’s (GSK) 2Q17 revenues, which are expected to total nearly 7.3 billion British pounds.

    By Mike Benson
  • uploads///Chart  Inno
    Earnings Report

    Novartis in 2Q17: Performance of Innovative Medicines

    The overall contribution of the Innovative Medicines segment was ~67.6% at $8.28 billion for 2Q17.

    By Mike Benson
  • uploads///Chart  Inno Medicines
    Earnings Report

    Novartis’s 2Q17 Estimates: Innovative Medicines Segment

    The overall contribution of Novartis’s (NVS) Innovative Medicines segment is ~67.0% of its total revenues.

    By Mike Benson
  • uploads///abbv
    Miscellaneous

    The Top Dividend-Growing Healthcare and Industrials Stocks

    The sector has seen the weakest growth in its top and bottom lines due to uncertainty in terms of sector reforms.

    By Amanda Lawrence
  • uploads///QCOM
    Miscellaneous

    Dividend Growth for Qualcomm and Crown Castle International

    Qualcomm (QCOM) recorded a year-over-year decline in revenues for 2Q17 after growth in the preceding quarter.

    By Amanda Lawrence
  • uploads///Chart  EPS
    Company & Industry Overviews

    What Happened to Novartis’s Valuation after 1Q17?

    Novartis reported EPS of $1.13 on revenues of $11.54 billion for 1Q17, which represents 2% YoY operational growth in revenues.

    By Mike Benson
  • uploads///Chart  GCHC
    Company & Industry Overviews

    Sanofi’s Generics and Consumer Healthcare Business in 1Q17

    Sanofi’s (SNY) Generics business contributes ~5% to the group’s total revenues.

    By Mike Benson
  • uploads///Chart  Inno Medicines
    Earnings Report

    Novartis’s 1Q17 Estimates: Innovative Medicines Segment

    Novartis’s (NVS) Innovative Medicines segment includes products for therapeutic areas such as oncology, cardiometabolic, immunology, and dermatology.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Why Sanofi’s Consumer Healthcare and Generics Segment Still Matters

    Sanofi’s (SNY) Consumer Healthcare segment reported a 1.6% YoY (year-over-year) fall in revenues at 3.33 billion euros (about $3.56 billion) in 2016.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Could Novartis’s CTL019 Capture Significant Market Share?

    Currently, an estimated 7,000 patients suffer from pediatric ALL in the US, Europe, Japan, Canada, and Israel.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    Are Sanofi’s Established Prescription Products Adding Up?

    Sanofi’s (SNY) Established Prescription Products segment contributed nearly 30.5% of the company’s total revenues in 2016.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Inside Sanofi’s Overall Revenue Performance in 2016

    Sanofi (SNY) reported a YoY (year-over-year) revenue growth of ~1.2% at constant exchange rates for 2016.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Why Entresto Could Become Key Growth Driver for Novartis in 2017

    Novartis (NVS) expects modest prescription growth for its heart failure drug, Entresto, in 1Q17.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    Novartis’s Valuation Compared to Its Peers’

    Novartis’s valuation has followed the industry’s overall trend over the last five years. Whether the healthcare sector’s valuation rises or falls, Novartis will definitely be affected.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    What Will Drive AstraZeneca’s Oncology Revenues in 2017?

    In 2016, AstraZeneca’s (AZN) poly ADP-ribose polymerase (or PARP) inhibitor, Lynparza, managed to report revenues close to $218 million.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    Growth of AstraZeneca’s Oncology Segment in 2016

    The revenues for AstraZeneca’s (AZN) Oncology segment rose ~20% at constant exchange rates in 2016.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    These Prescription Products Matter to Sanofi’s Growth

    Sanofi’s (SNY) established prescription products contributed nearly 28.9% of the company’s total 4Q16 revenues.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Novartis’s Valuation after the 4Q16 Results

    On January 31, 2017, Novartis was trading at a forward PE multiple of ~15.2x. Based on its last-five-year multiple range, this is neither high nor low.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Inside Novartis’s Generics Performance in 4Q16

    Sandoz, the Generics segment of Novartis (NVS), is second-largest generic medicines provider worldwide and number one in differentiated generics.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Analysts Expect Negative Growth for Novartis in 4Q16

    Analysts expect an ~1.1% decline in Novartis’s (NVS) 4Q16 revenues to ~$12.4 billion following the effects of the acquisition and divestiture of several products.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Did Novartis’s Innovative Medicines Segment Perform?

    The overall contribution of the innovative medicines segment was ~67% at $8,173 million for 3Q16.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    AstraZeneca’s Lynparza Is Still a Leading PARP Inhibitor in 2016

    On October 26, 2016, AstraZeneca (AZN) announced that Lynparza managed to demonstrate a superior clinical profile in the Phase 3 SOLO-2 trial.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Teva’s Research Pipeline to Culminate in Many New Drug Launches?

    Teva Pharmaceutical’s (TEVA) generic research pipeline is expected to result in more than 30 first-to-file (or FTF) launches in 2016 and 2017.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Teva Pharmaceutical Expects Mid-Single-Digit Growth for Generics

    In 3Q16, Teva Pharmaceutical Industries (TEVA) reported increased price erosion of about 7.0% for its US-based business compared to 3Q15.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    Performance of Novartis’s Innovative Medicines Segment in 3Q16

    Novartis’s (NVS) Innovative Medicines segment contributed ~67.0% at $8.2 billion for 3Q16.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Changes in Novartis’s Valuation for 3Q16

    Based on the last five years’ multiple range, Novartis’s current valuation is neither high nor low. The PE multiple has ranged from ~9.0x to ~20.0x.

    By Mike Benson
  • uploads///Fund Flows
    Company & Industry Overviews

    Bernstein: Excess Risk Aversion Has Made Investors ‘Wallflowers’

    In his November Insights newsletter, Richard Bernstein stated, “It is incredible that investors have basically been wallflowers during the second longest bull market of the post-war period.”

    By David Ashworth
  • uploads///Chart
    Earnings Report

    Inside AstraZeneca’s Oncology Segment Growth in 3Q15

    AstraZeneca’s (AZN) Oncology segment is another key company focus area. The segment’s contribution rose to over 17% in 3Q16.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Inside AstraZeneca’s Revenue Fall in 3Q16

    For 3Q16, AstraZeneca (AZN) reported a 4.1% fall in its top line at $5.7 billion.

    By Mike Benson
  • uploads///SP  Sector Returns in YTD
    Company & Industry Overviews

    Richard Bernstein: Don’t Fear the Bear Market

    A legitimate bull market In this series, we’ve taken a look at Richard Bernstein’s views on investors’ fear of an impending bear market. In Richard Bernstein Advisors’ October Insights newsletter, he rejects the notion that the current rise in US stocks (SPLV) (OEF) has been brought about only by the Fed’s easy monetary policy. In the […]

    By David Ashworth
  • uploads///Graph
    Company & Industry Overviews

    Volume Growth and Product Mix to Drive NVO’s Insulin Sales

    From 2011 to 2015, Novo Nordisk’s (NVO) diabetes care franchise sales have risen at a compounded average growth rate (or CAGR) of approximately 11.5%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Diabetes Care Market Expected to Offer Strong Growth for Novo Nordisk

    With a 46% share of the global insulin market, Novo Nordisk (NVO) is currently a leading player in the diabetes care segment.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    A Look at Teva’s Dominance in the Biosimilar Space

    As one of the early entrants in biosimilars, Teva Pharmaceutical Industries (TEVA) has managed to become one of the biggest players in the biosimilar space.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Teva Pharmaceutical Leads in Global Generic Pharmaceutical Space

    After the acquisition of Allergan’s generics business and divestitures, Teva Pharmaceutical has become a leading player in the global generic industry.

    By Margaret Patrick
  • uploads///anr
    Company & Industry Overviews

    Analyst Price Targets and Recommendations for Sanofi

    According to a Bloomberg consensus of five brokerage firms on September 12, 60.0% of analysts rated Sanofi as a “buy,” while 40% rated it as a “hold.”

    By Jillian Dabney
  • uploads///franchise wise revenue
    Company & Industry Overviews

    How Sanofi’s Various Franchises Performed in 2Q16

    Established Rx is Sanofi’s largest franchise, with a share of 30% of total sales in 2Q16 totaling 2.6 billion euros, or about $2.9 billion.

    By Jillian Dabney
  • uploads///revenue and margin
    Company & Industry Overviews

    How Sanofi’s Franchises Could Perform into 2017

    During the second quarter of 2016, Sanofi’s aggregate sales declined by 0.2% to about $10 billion. Its diabetes and cardiovascular franchise fell by 2%.

    By Jillian Dabney
  • uploads///PE
    Company & Industry Overviews

    Understanding Sanofi’s Discounted Valuation

    On September 8, 2016, Sanofi was trading at a forward PE multiple of 12.17x—at a greater discount than peers Eli Lilly, Merck & Company, and Novo Nordisk.

    By Jillian Dabney
  • uploads///CHC business position
    Company & Industry Overviews

    Why Is Sanofi Expanding in the CHC Space?

    Sanofi (SNY) plans to become a leading company in the CHC business. The asset swap will exclude Boehringer Ingelheim’s CHC business in China.

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    Litigation Has Teva Pharmaceutical’s Copaxone 40 mg All Tied Up

    Teva Pharmaceutical is currently facing litigations in which competitors are challenging the orange book patents it holds for Copaxone 40 mg.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    Why AstraZeneca Reported Negative Growth in 2Q16

    AstraZeneca reported a gradual shift of positive contributors from key drugs such as Nexium and Synagis to new products in growth platforms.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Is AstraZeneca’s Valuation Improving Compared to Peers?

    AstraZeneca’s stock value has increased 11.9% over the last 12 months. Analysts estimate that it has the potential to return 17.8% over the next 12 months.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    This Changed Sanofi’s Profitability in 2Q16

    Sanofi reported a net profit of ~1.7 billion euros (about $1.9 billion) in 2Q16—a decline of 8.7% in net profits over 2Q15.

    By Mike Benson
  • uploads///Kellogg and Peers Dividend Yield
    Consumer

    How Much Did Kellogg Return to Shareholders?

    Kellogg announced a quarterly dividend of $0.50 per share on its common stock—paid on June 15 to shareowners of record at the close of business on June 1.

    By Sushree Mohanty
  • uploads///Chart
    Earnings Report

    Why Analysts Think AstraZeneca’s Revenues Will Fall in 2Q16

    AstraZeneca (AZN) reported an increase of 1% in its top line to $6.1 billion in its 1Q16 results.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    How Do the Majority of Analysts Rate Novartis after 2Q16?

    Novartis’s annual estimated EPS for 2016 came in at $4.80, with a fall of ~1.5% in annual revenues to ~$48.7 billion and a gross margin rising to 73.1%.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    GlaxoSmithKline Segments That Drive Company’s Rising Revenues

    Analysts expect a growth of ~7.8% in GlaxoSmithKline’s (GSK) 2Q16 revenues, to 6.4 billion British pounds.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Inside the Foreign Exchange Impact on Novartis’s Growth in 2Q16

    Novartis (NVS) reported no change in revenues on a constant currency basis for 2Q16, as compared to 2Q15, in its earnings release on July 19, 2016.

    By Mike Benson
  • uploads///Article
    Company & Industry Overviews

    Novartis’s Sandoz Division Accounts for 18% of Net Sales in 2015

    Sandoz accounted for $9.2 billion, or 18%, of Novartis’s net sales during 2015.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Teva Expects to Maintain Profitability despite Tough Pricing Environment

    Since February 2016, generic drug manufacturers, wholesalers, and distributors have been expressing increased concern over the expected price deflation in the industry.

    By Margaret Patrick
  • uploads///Int rate driven
    Company & Industry Overviews

    Portfolio Construction in Interest Rate–Driven Bull Markets

    In a falling interest rate environment, the PE ratio rises because investors are keen to increase the time horizon of their investments.

    By David Ashworth
  • uploads///Chart
    Company & Industry Overviews

    Trends for Sanofi Pasteur: The Human Vaccines Segment

    Sanofi Pasteur, the Human Vaccines business of Sanofi (SNY), reported an 8.2% increase at constant exchange rates in its 1Q16 revenues at 625 million euros.

    By Mike Benson
  • uploads/// vision
    Earnings Report

    What’s Kellogg’s 2020 Vision Strategy?

    Kellogg plans to return its “Kashi” brand to growth in 2016. It aims to lead in plant-based nutrition and win with “food forward” consumers.

    By Sushree Mohanty
  • uploads///Chart
    Earnings Report

    Why Did Sandoz Report Operational Growth?

    Sandoz is the generics arm of Novartis (NVS). For 1Q16, Sandoz contributed ~21.1% of the total revenue at $2.44 billion.

    By Mike Benson
  • uploads///Graph
    Miscellaneous

    Lesinurad: A Selective Uric Acid Reabsorption Inhibitor for Gout

    Lesinurad, originally developed by Ardea Biosciences, was acquired by AstraZeneca through the acquisition of Ardea in June 2012. It works to reduce the uric acid levels in gout patients.

    By Margaret Patrick
  • uploads///Chart
    Macroeconomic Analysis

    A Methodology Overview of the First Trust Value Line Dividend Index Fund

    First Trust Value Line Dividend Index Fund is a smart beta fund by First Trust that seeks to replicate the performance of the Value Line Dividend Index.

    By Ivan Kading
  • uploads///Chart
    Macroeconomic Analysis

    A Fund Flow Analysis of the First Trust Value Line Dividend Index Fund

    Fiscal 2015 has seen a considerable falls in the First Trust Value Line Dividend Index Fund due to the weak economic environment and SPY’s poor performance.

    By Ivan Kading
  • uploads///Archer Danielss Earnings per Share versus Consensus Estimates
    Earnings Report

    Archer Daniels Midland Misses Consensus Earnings Estimates

    Archer Daniels Midland reported earnings per share of $0.60 in 3Q15, missing consensus estimates by 18%. When compared to 3Q14, EPS has fallen by 30%.

    By Sushree Mohanty
  • uploads///ebdeaadcdaeeeca
    Macroeconomic Analysis

    A Comparative Analysis of DVY

    The iShares Select Dividend ETF (DVY) is majorly invested in the utilities, financials, and consumer staples sectors.

    By Ivan Kading
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.